The approval was based on data from the phase 1 ELEVATE-PLUS trials, which showed the acalabrutinib 100mg tablets were bioequivalent to the acalabrutinib 100mg capsules.
Zanubrutinib can improve progression-free survival, when compared with bendamustine-rituximab, in previously untreated CLL/SLL, a phase 3 trial suggests.
Researchers investigated a hypothesis that posttreatment bone marrow biopsy may not be needed after confirming complete response on imaging in patients with follicular lymphoma.
Researchers sought to determine whether response-adapted sequential salvage therapy would be effective in patients with relapsed/refractory classical Hodgkin lymphoma.
Researchers sought to determine whether adding pembrolizumab to consolidation chemotherapy would be effective in pediatric patients with high-risk classic Hodgkin lymphoma.
Researchers sought to determine whether adding rituximab to axicabtagene ciloleucel would have efficacy in patients with refractory large B-cell lymphoma.
Researchers sought to determine whether evaluating circulating microRNAs in cerebrospinal fluid would be a sensitive approach for detecting secondary CNS involvement in B-NHL
A study compared patients with diffuse large B-cell lymphoma with a 1:10 cohort from the general population to determine the risk of cardiovascular events in patients receiving doxorubicin-containing regimens.
Researchers sought to determine whether the GALEN regimen would yield favorable clinical outcomes in patients with previously untreated follicular lymphoma.
Of the NHL patients with neutralizing antibodies against the WA1/2020 SARS-CoV-2 strain, 70% had antibodies against the delta variant, and 33% had antibodies against the omicron variant.
Researchers sought to determine the dose and safety profile for mosunetuzumab administered for patients with aggressive and indolent relapsed or refractory B-NHLs.
Researchers sought to determine whether brentuximab vedotin with bendamustine would be effective in pediatric patients with relapsed or refractory Hodgkin lymphoma.
A retrospective study of patient data sought to determine if bone marrow infiltration is linked to adverse effect severity in patients with CD20-positive B-NHL.